Prestige Consumer Healthcare will release fiscal Q1 2026 earnings on August 7, 2025, followed by a conference call at 8:30 a.m. ET.
Quiver AI Summary
Prestige Consumer Healthcare Inc. announced that it will release its fiscal 2026 first quarter earnings on August 7, 2025, prior to market opening. A conference call to discuss the earnings will take place at 8:30 a.m. ET that day, accessible via a live internet webcast on the company’s Investor Relations page. Participants can also register for dial-in details if they prefer to join by phone, and are encouraged to connect 10 minutes early. A replay of the call will be available for about a week afterward. Prestige Consumer Healthcare markets a variety of consumer healthcare products, including brands like Monistat, BC, and Dramamine, across the U.S., Canada, Australia, and other international markets.
Potential Positives
- Announcement of a scheduled earnings release and conference call demonstrates transparency and commitment to keeping shareholders informed.
- The earnings call provides an opportunity for real-time engagement between the company and investors, potentially strengthening investor relations.
- The availability of a conference call replay allows a broader audience to access the information, enhancing communication with stakeholders.
Potential Negatives
- None
FAQ
When will Prestige Consumer Healthcare release its fiscal 2026 Q1 earnings?
Prestige Consumer Healthcare will issue its fiscal 2026 first quarter earnings release on August 7, 2025, before market opening.
What time is the conference call for fiscal 2026 Q1 earnings?
The conference call to discuss the Q1 earnings will be held at 8:30 a.m. ET on August 7, 2025.
How can I access the fiscal 2026 earnings conference call?
You can access the live Internet webcast of the conference call on the Investor Relations page of www.prestigeconsumerhealthcare.com.
Will there be a replay of the earnings call?
Yes, a conference call replay will be available for approximately one week after the live call on the Company’s Investor Relations page.
What brands does Prestige Consumer Healthcare offer?
Prestige Consumer Healthcare’s brands include Monistat®, Summer’s Eve®, and several others across various healthcare categories.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PBH Insider Trading Activity
$PBH insiders have traded $PBH stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PBH stock by insiders over the last 6 months:
- ADEL MEKHAIL (EVP, Marketing & Sales) has made 0 purchases and 2 sales selling 11,083 shares for an estimated $959,270.
- MARY BETH FRITZ (SVP Quality & Regulatory) sold 1,678 shares for an estimated $151,020
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PBH Hedge Fund Activity
We have seen 146 institutional investors add shares of $PBH stock to their portfolio, and 174 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VICTORY CAPITAL MANAGEMENT INC removed 519,066 shares (-31.2%) from their portfolio in Q1 2025, for an estimated $44,624,104
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC added 493,199 shares (+45.3%) to their portfolio in Q1 2025, for an estimated $42,400,318
- LSV ASSET MANAGEMENT removed 283,826 shares (-96.3%) from their portfolio in Q1 2025, for an estimated $24,400,521
- INVESCO LTD. added 261,537 shares (+24.7%) to their portfolio in Q1 2025, for an estimated $22,484,335
- BLACKROCK, INC. removed 248,522 shares (-2.9%) from their portfolio in Q1 2025, for an estimated $21,365,436
- ARIEL INVESTMENTS, LLC removed 243,082 shares (-8.8%) from their portfolio in Q1 2025, for an estimated $20,897,759
- ARISTOTLE CAPITAL BOSTON, LLC removed 231,132 shares (-39.6%) from their portfolio in Q1 2025, for an estimated $19,870,418
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PBH Analyst Ratings
Wall Street analysts have issued reports on $PBH in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 02/13/2025
- DA Davidson issued a "Buy" rating on 02/07/2025
- Canaccord Genuity issued a "Buy" rating on 02/07/2025
To track analyst ratings and price targets for $PBH, check out Quiver Quantitative's $PBH forecast page.
$PBH Price Targets
Multiple analysts have issued price targets for $PBH recently. We have seen 5 analysts offer price targets for $PBH in the last 6 months, with a median target of $99.0.
Here are some recent targets:
- Ryland Conrad from RBC Capital set a target price of $99.0 on 05/08/2025
- John Zamparo from Scotiabank set a target price of $91.0 on 05/08/2025
- Rupesh Parikh from Oppenheimer set a target price of $93.0 on 02/13/2025
- Linda Bolton Weiser from DA Davidson set a target price of $104.0 on 02/07/2025
- Susan Anderson from Canaccord Genuity set a target price of $100.0 on 02/07/2025
Full Release
TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com . To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat ® and Summer’s Eve ® women's health products, BC ® and Goody's ® pain relievers, Clear Eyes ® and TheraTears® eye care products, DenTek ® specialty oral care products, Dramamine ® motion sickness treatments, Fleet ® enemas and glycerin suppositories, Chloraseptic ® and Luden's ® sore throat treatments and drops, Compound W ® wart treatments, Little Remedies ® pediatric over-the-counter products, Boudreaux’s Butt Paste ® diaper rash ointments, Nix ® lice treatment, Debrox ® earwax remover, Gaviscon ® antacid in Canada, and Hydralyte ® rehydration products and the Fess ® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com .
